The IG/TR Next Generation Marker Screening Developed within Euroclonality-NGS Consortium Is Successful in 94% of Acute Lymphoblastic Leukemia Samples

BLOOD

Kotrova, M; Knecht, H; Herrmann, D; Schwarz, M; Olsen, K; Trautmann, H; Goekbuget, N; Pott, C; Darzentas, N; Bruggemann, M, 2018: The IG/TR Next Generation Marker Screening Developed within Euroclonality-NGS Consortium Is Successful in 94% of Acute Lymphoblastic Leukemia Samples. BLOOD 132, doi: 10.1182/blood-2018-99-112828

Research Groups:

CEITEC authors: